Alzamend Neuro, Inc. (NasdaqCM: ALZN)
Health Care · Biotechnology · US
$1.60
+2.56% today · -35.5% 1Y
Alzamend Neuro, Inc. (NasdaqCM: ALZN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.47M and employs 6 people.
Over the last twelve months the share price has lost 35.5%, trading between 0.84 and 2.68.
Tweenvest scores Alzamend Neuro, Inc. across four factors: quality 25/100. Its strongest factor is quality.
ALZN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.47M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.63
- Dividend yield
- —
- Beta (5Y)
- 0.19
- 52-week high
- $2.68
- 52-week low
- $0.84
- Avg volume (3M)
- —
- Shares outstanding
- 4.79M
- Employees
- 6
- Next earnings
- —
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
- ISIN
- US02262M6057
- Founded
- 2016
- Listed since
- Jun 15, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.75 | -0.02% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $441.55 | -0.16% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €898.00 | +2.14% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.87 | -0.60% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.